menu
    • menu
    [{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Oxiconazole Nitrate","moa":"Ergosterol biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sandoz B2B \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ ANI Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Oxiconazole

    Menu

    Oxiconazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sandoz B2B

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sandoz B2B

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxiconazole Nitrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs

                            Details : ANI Pharmaceuticals has acquired new drug applications for OXISTAT Lotion, VEREGEN Ointment, and Pandel Cream and the abbreviated new drug application for ApexiCon E Cream from Sandoz Inc. Pandel Cream will be transitioned later upon receiving the requis...

                            Brand Name : Oxistat

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 06, 2021

                            Lead Product(s) : Oxiconazole Nitrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth